Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial

  1. Grimm, M.-O.
  2. Esteban, E.
  3. Barthélémy, P.
  4. Schmidinger, M.
  5. Busch, J.
  6. Valderrama, B.P.
  7. Charnley, N.
  8. Schmitz, M.
  9. Schumacher, U.
  10. Leucht, K.
  11. Foller, S.
  12. Baretton, G.
  13. Duran, I.
  14. de Velasco, G.
  15. Priou, F.
  16. Maroto, P.
  17. Albiges, L.
  18. Barone, C.
  19. Castellano, D.
  20. Chevreau, C.
  21. Gajate Borau, P.
  22. Gopalakrishnan, S.
  23. Grande, E.
  24. Hamid, A.
  25. Heinzelbecker, J.
  26. Janssen, M.
  27. Kopecký, J.
  28. Kubala, E.
  29. Loidl, W.
  30. Lorch, A.
  31. Melichar, B.
  32. Lainez Milagro, N.
  33. Niegisch, G.
  34. Ohlmann, C.
  35. Sacré, A.
  36. Sarwar, N.
  37. Schinzari, G.
  38. Schrijvers, D.
  39. Tartas, S.
  40. Wirth, M.
  41. Wolter, P.
  42. Zemanova, M.
  43. Show all authors +
Journal:
The Lancet Oncology

ISSN: 1474-5488 1470-2045

Year of publication: 2023

Volume: 24

Issue: 11

Pages: 1252-1265

Type: Article

DOI: 10.1016/S1470-2045(23)00449-7 GOOGLE SCHOLAR

Sustainable development goals